| B cells are associated with survival and immunotherapy response in sarcoma F Petitprez, A de Reyniès, EZ Keung, TWW Chen, CM Sun, J Calderaro, ... Nature 577 (7791), 556-560, 2020 | 1605 | 2020 |
| Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open … YA Vano, R Elaidi, M Bennamoun, C Chevreau, D Borchiellini, D Pannier, ... The Lancet Oncology 23 (5), 612-624, 2022 | 109 | 2022 |
| iPS-cell-derived microglia promote brain organoid maturation via cholesterol transfer DS Park, T Kozaki, SK Tiwari, M Moreira, A Khalilnezhad, F Torta, N Olivié, ... Nature 623 (7986), 397-405, 2023 | 83 | 2023 |
| A epistemologia de Maturana MA Moreira Ciência & Educação (Bauru) 10, 597-606, 2004 | 77 | 2004 |
| Tertiary lymphoid structures and B cells: clinical impact and therapeutic modulation in cancer C Sautes-Fridman, J Verneau, CM Sun, M Moreira, TWW Chen, M Meylan, ... Seminars in Immunology 48, 101406, 2020 | 69 | 2020 |
| Tumor microenvironment features as predictive biomarkers of response to immune checkpoint inhibitors (ICI) in metastatic clear cell renal cell carcinoma (mccRCC) A Simonaggio, N Epaillard, C Pobel, M Moreira, S Oudard, YA Vano Cancers 13 (2), 231, 2021 | 62 | 2021 |
| Immune-desert tumor microenvironment in thoracic SMARCA4-deficient undifferentiated tumors with limited efficacy of immune checkpoint inhibitors J Gantzer, G Davidson, B Vokshi, N Weingertner, A Bougoüin, M Moreira, ... The oncologist 27 (6), 501-511, 2022 | 42 | 2022 |
| BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer N Epaillard, A Simonaggio, R Elaidi, F Azzouz, E Braychenko, C Thibault, ... Bulletin du Cancer 107 (5), eS22-eS27, 2020 | 41 | 2020 |
| Resistance to cancer immunotherapy in metastatic renal cell carcinoma M Moreira, C Pobel, N Epaillard, A Simonaggio, S Oudard, YA Vano Cancer Drug Resistance 3 (3), 454, 2020 | 24 | 2020 |
| 1451MO In-situ immune markers predict nivolumab (N)+/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the … M Meylan, CM Sun, RT Elaidi, M Moreira, A Bougouin, V Verkarre, ... Annals of Oncology 33, S1207, 2022 | 4 | 2022 |
| Multicellular tumor spheroid model to study the multifaceted role of tumor-associated macrophages in PDAC N Bidan, G Dunsmore, M Ugrinic, M Bied, M Moreira, C Deloménie, ... Drug Delivery and Translational Research 14 (8), 2085-2099, 2024 | 2 | 2024 |
| Impact of molecular signatures on the choice of systemic treatment for metastatic kidney cancer A Simonaggio, N Epaillard, R Elaidi, CM Sun, M Moreira, S Oudard, ... Bulletin du Cancer 107 (5S), S24-S34, 2020 | 2 | 2020 |
| Impact des signatures moléculaires sur le choix du traitement systémique du cancer du rein métastatique A Simonaggio, N Epaillard, R Elaidi, CM Sun, M Moreira, S Oudard, ... Bulletin du Cancer 107 (5), S24-S34, 2020 | 1 | 2020 |
| Induced pluripotent stem cell-derived macrophages as a platform for modelling human disease SK Tiwari, WJ Wong, M Moreira, C Pasqualini, F Ginhoux Nature Reviews Immunology 25 (2), 108-124, 2025 | | 2025 |
| Immune-desert tumor microenvironment in SMARCA4-deficient thoracic sarcomas with limited efficacy of immune checkpoint inhibitors. J Gantzer, G Davidson, B Vokshi, N Weingertner, A Bougoüin, M Moreira, ... Journal of Clinical Oncology 39 (15_suppl), 11552-11552, 2021 | | 2021 |